Who to send
The Valeda Light Delivery System is indicated for patients with dry age-related macular degeneration who have:
- Best-corrected visual acuity of 20/32 through 20/70
- At least three medium drusen (larger than 63 and up to 125 microns), or large drusen (larger than 125 microns), or non-central geographic atrophy
Patients with neovascular AMD in the eye to be treated, or with other visually significant ocular disease, are not candidates. Please refer to the device labeling for the full indications and contraindications. If you are unsure whether a patient qualifies, send them. We would rather confirm than have someone miss the window.
What we do
- Consult. Best-corrected acuity, Optos widefield imaging and Zeiss OCT to confirm the patient meets the indication.
- Treatment. Nine sessions over three weeks per series, repeated about every four months, per the LIGHTSITE III protocol.
- Monitoring during treatment. Acuity and OCT at intervals, so there is an objective record of response.
What you get back
- A written consult report after the first visit, stating whether the patient qualifies and why
- Updates after each treatment series, with acuity and imaging
- Your patient. We do not take over their primary or medical eye care, their glasses or their contact lenses. If we find something outside dry AMD, we send it to you.
How to refer
- Fax: (845) 255-1201. A recent OCT and your last acuity are helpful but not required.
- Phone or text: (845) 255-4696
- Or have the patient book directly. No referral is required. We will ask who their eye doctor is and send you the report.
About the evidence
LIGHTSITE III was a prospective, double-masked, sham-controlled trial at ten US retina centers. It met its primary endpoint, with a statistically significant BCVA benefit for PBM over sham at the 13 and 21 month analyses. Per the labeling, treated eyes averaged approximately one ETDRS line better than untreated eyes at about two years. The FDA granted De Novo marketing authorization in November 2024. Dr. Harnos is glad to talk through the data, the protocol or a specific patient by phone.